Literature DB >> 33040092

Attention-deficit/hyperactivity disorder and the explore/exploit trade-off.

Merideth A Addicott1, John M Pearson2, Julia C Schechter2, Jeffrey J Sapyta2, Margaret D Weiss3, Scott H Kollins2.   

Abstract

The ability to maximize rewards and minimize the costs of obtaining them is vital to making advantageous explore/exploit decisions. Exploratory decisions are theorized to be greater among individuals with attention-deficit/hyperactivity disorder (ADHD), potentially due to deficient catecholamine transmission. Here, we examined the effects of ADHD status and methylphenidate, a common ADHD medication, on explore/exploit decisions using a 6-armed bandit task. We hypothesized that ADHD participants would make more exploratory decisions than controls, and that MPH would reduce group differences. On separate study days, adults with (n = 26) and without (n = 23) ADHD completed the bandit task at baseline, and after methylphenidate or placebo in counter-balanced order. Explore/exploit decisions were modeled using reinforcement learning algorithms. ADHD participants made more exploratory decisions (i.e., chose options without the highest expected reward value) and earned fewer points than controls in all three study days, and methylphenidate did not affect these outcomes. Baseline exploratory choices were positively associated with hyperactive ADHD symptoms across all participants. These results support several theoretical models of increased exploratory choices in ADHD and suggest the unexplained variance in ADHD decisions may be due to less value tracking. The inability to suppress actions with little to no reward value may be a key feature of hyperactive ADHD symptoms.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33040092      PMCID: PMC8027173          DOI: 10.1038/s41386-020-00881-8

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  48 in total

Review 1.  The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics.

Authors:  Edmund J S Sonuga-Barke
Journal:  Neurosci Biobehav Rev       Date:  2003-11       Impact factor: 8.989

2.  Executive functioning in adult ADHD: a meta-analytic review.

Authors:  A Marije Boonstra; Jaap Oosterlaan; Joseph A Sergeant; Jan K Buitelaar
Journal:  Psychol Med       Date:  2005-08       Impact factor: 7.723

3.  Neuropsychological analyses of comorbidity between reading disability and attention deficit hyperactivity disorder: in search of the common deficit.

Authors:  Erik G Willcutt; Bruce F Pennington; Richard K Olson; Nomita Chhabildas; Jacqueline Hulslander
Journal:  Dev Neuropsychol       Date:  2005       Impact factor: 2.253

4.  Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

Authors:  J Biederman; E Mick; S V Faraone
Journal:  Am J Psychiatry       Date:  2000-05       Impact factor: 18.112

Review 5.  Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life.

Authors:  Peter M Wehmeier; Alexander Schacht; Russell A Barkley
Journal:  J Adolesc Health       Date:  2010-01-04       Impact factor: 5.012

6.  Subtype differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment.

Authors:  Esther Sobanski; Daniel Brüggemann; Barbara Alm; Sebastian Kern; Alexandra Philipsen; Hannah Schmalzried; Bernd Hesslinger; H Waschkowski; Marcella Rietschel
Journal:  Eur Psychiatry       Date:  2007-11-19       Impact factor: 5.361

Review 7.  Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis.

Authors:  Viktória Simon; Pál Czobor; Sára Bálint; Agnes Mészáros; István Bitter
Journal:  Br J Psychiatry       Date:  2009-03       Impact factor: 9.319

8.  Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD.

Authors:  Timothy E Wilens; Joseph Biederman; Stephen V Faraone; Marykate Martelon; Diana Westerberg; Thomas J Spencer
Journal:  J Clin Psychiatry       Date:  2009-11       Impact factor: 4.384

9.  Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review.

Authors:  Aaron S Hervey; Jeffery N Epstein; John F Curry
Journal:  Neuropsychology       Date:  2004-07       Impact factor: 3.295

10.  Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence From a Four-Decade Longitudinal Cohort Study.

Authors:  Terrie E Moffitt; Renate Houts; Philip Asherson; Daniel W Belsky; David L Corcoran; Maggie Hammerle; HonaLee Harrington; Sean Hogan; Madeline H Meier; Guilherme V Polanczyk; Richie Poulton; Sandhya Ramrakha; Karen Sugden; Benjamin Williams; Luis Augusto Rohde; Avshalom Caspi
Journal:  Am J Psychiatry       Date:  2015-05-22       Impact factor: 18.112

View more
  4 in total

1.  Sex differences in learning from exploration.

Authors:  Cathy S Chen; Evan Knep; Autumn Han; R Becket Ebitz; Nicola M Grissom
Journal:  Elife       Date:  2021-11-19       Impact factor: 8.140

2.  Exploration heuristics decrease during youth.

Authors:  Magda Dubois; Aislinn Bowler; Madeleine E Moses-Payne; Johanna Habicht; Rani Moran; Nikolaus Steinbeis; Tobias U Hauser
Journal:  Cogn Affect Behav Neurosci       Date:  2022-05-19       Impact factor: 3.526

3.  Striatal dopamine dissociates methylphenidate effects on value-based versus surprise-based reversal learning.

Authors:  Ruben van den Bosch; Britt Lambregts; Jessica Määttä; Lieke Hofmans; Danae Papadopetraki; Andrew Westbrook; Robbert-Jan Verkes; Jan Booij; Roshan Cools
Journal:  Nat Commun       Date:  2022-08-24       Impact factor: 17.694

4.  Decision flexibilities in autism spectrum disorder: an fMRI study of moral dilemmas.

Authors:  Shisei Tei; Mizuki Tanicha; Takashi Itahashi; Yuta Y Aoki; Haruhisa Ohta; Chenyu Qian; Ryu-Ichiro Hashimoto; Motoaki Nakamura; Hidehiko Takahashi; Nobumasa Kato; Junya Fujino
Journal:  Soc Cogn Affect Neurosci       Date:  2022-10-03       Impact factor: 4.235

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.